arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Enveric Biosciences, Inc.

ENVB
$1.55 ▼ -0.03 (-1.58%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enveric Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -29.6%
FCF / Share $-0.61
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.48M
↓ -7.3%
Net Income Profit after all expenses
$-1.63M
↑ +25.2%
Operating Margin Operating profit as % of sales
-13.2%
↑ +8.2%
FCF / Share Free cash flow per share
$-0.61
↑ +59.0%
Long-Term Debt Long-term obligations
$1.70K
↓ -99.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
0
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 59 quarters